Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
Trial status:Recruitment Complete
Study Identifier:
GCT1056-01
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
Genmab
Recruitment Complete
Trial details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female & Male
Age
18+
Estimated Trial Date
Oct 2022 - Dec 2025
Protocol summary
The main purpose of this first-in-human study of GEN1056, is to evaluate safety. In addition, the study will determine the recommended dose and frequency for subsequent clinical studies and will assess the preliminary anti-tumor activity of GEN1056. GEN1056 will be studied in patients with advanced or metastatic solid cancer, for whom standard of care (SOC) therapy is not an option. All participants will get GEN1056.
Trial locations
Location
Status
Location
ARENSIA Exploratory Medicine LLC
Tbilisi, Georgia
Status
Location
ARENSIA Exploratory Medicine Phase I Unit
Chisinau, Republic of Moldova
Status
Location
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Status
Location
Centro Integral Oncologico Clara Campal
Madrid, Spain
Status
Location
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Status
Location
MD Anderson Cancer Centre
Madrid, Spain
Status